Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer

BACKGROUND: Currently available third- or later-line therapy for metastatic colorectal cancer (mCRC) is limited in its efficacy, with a weak survival benefit in patients who progressed after two or more lines of standard therapy. Our retrospective study aimed to explore the value of bevacizumab plus...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Qiong, Yin, Chenxi, Liao, Fangxin, Huang, Yuanyuan, He, Wenzhuo, Jiang, Chang, Guo, Guifang, Zhang, Bei, Xia, Liangping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562721/
https://www.ncbi.nlm.nih.gov/pubmed/26366095
http://dx.doi.org/10.2147/OTT.S88679

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562721/
https://www.ncbi.nlm.nih.gov/pubmed/26366095
http://dx.doi.org/10.2147/OTT.S88679

Ejemplares similares